Trial Profile
Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms RRTCLAlloSCT
- 17 Aug 2022 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 17 Aug 2022 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 07 Sep 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2026.